Flex Biomedical Raises Nearly $1M to Further Develop Polymer to Treat Osteoarthritis

Flex Biomedical, a privately-held orthopedics company in Boston, has raised $985,000 to advance its lead product, the Flex Polymer, a synthetic polymer to treat osteoarthritis.

Advertisement

The funding includes a $150,000 loan from the state of Wisconsin and investments from several private sources in Wisconsin.

In addition, the company announced it is moving its operations to Madison, Wis.

Read the release about Flex Biomedical.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.